These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 35590394)

  • 21. RNA N6-methyladenosine (m6A) modification in HNSCC: molecular mechanism and therapeutic potential.
    Sun X; Fu S; Yuan X; Pu X; Wang R; Wang X; Lu H
    Cancer Gene Ther; 2023 Sep; 30(9):1209-1214. PubMed ID: 37221404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N
    Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N6-Methyladenosine Modification Opens a New Chapter in Circular RNA Biology.
    Wu J; Guo X; Wen Y; Huang S; Yuan X; Tang L; Sun H
    Front Cell Dev Biol; 2021; 9():709299. PubMed ID: 34368159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N6-Methyladenosine-Sculpted Regulatory Landscape of Noncoding RNA.
    Zhang Z; Wei W; Wang H; Dong J
    Front Oncol; 2021; 11():743990. PubMed ID: 34722298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma.
    Wang G; Zeng D; Sweren E; Miao Y; Chen R; Chen J; Wang J; Liao W; Hu Z; Kang S; Garza LA
    J Invest Dermatol; 2023 Aug; 143(8):1579-1590.e5. PubMed ID: 36842525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of m6A-mediated PD-1/PD-L1 in antitumor immunity.
    Liu L; Liang L; Li H; Shao W; Yang C; Lin F; Liu J; Zhang J
    Biochem Pharmacol; 2023 Apr; 210():115460. PubMed ID: 36822438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-omics comprehensive analysis reveals the predictive value of N6-methyladenosine- related genes in prognosis and immune escape of bladder cancer.
    Liu Y; Pang Z; Wang J; Wang J; Ji B; Xu Y; He J; Zhang L; Han Y; Shen L; Xu W; Ren M
    Cancer Biomark; 2024; 40(1):79-94. PubMed ID: 38517777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes.
    Wei J; Fang DL; Zhou W; He YF
    J Gastrointest Oncol; 2021 Aug; 12(4):1860-1872. PubMed ID: 34532134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N6-Methyladenosine Regulator-Mediated Immue Patterns and Tumor Microenvironment Infiltration Characterization in Glioblastoma.
    Xiong W; Li C; Wan B; Zheng Z; Zhang Y; Wang S; Fan J
    Front Immunol; 2022; 13():819080. PubMed ID: 35359993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration in Ovarian Cancer.
    Luo Y; Sun X; Xiong J
    Front Cell Dev Biol; 2021; 9():794801. PubMed ID: 35087835
    [No Abstract]   [Full Text] [Related]  

  • 31. The potential role of m6A modifications on immune cells and immunotherapy.
    Gan L; Zhao Y; Fu Y; Chen Q
    Biomed Pharmacother; 2023 Apr; 160():114343. PubMed ID: 36758318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
    Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
    Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma.
    Xu H; Yin L; Xu Q; Xiang J; Xu R
    Cancer Cell Int; 2022 May; 22(1):199. PubMed ID: 35606813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential roles of N6-methyladenosine (m6A) in immune cells.
    Liu C; Yang Z; Li R; Wu Y; Chi M; Gao S; Sun X; Meng X; Wang B
    J Transl Med; 2021 Jun; 19(1):251. PubMed ID: 34103054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N6-methyladenosine modification: A potential regulatory mechanism in spinal cord injury.
    Liu D; Fan B; Li J; Sun T; Ma J; Zhou X; Feng S
    Front Cell Neurosci; 2022; 16():989637. PubMed ID: 36212687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy.
    Zhou X; Li C; Chen T; Li W; Wang X; Yang Q
    Mol Cancer; 2023 Feb; 22(1):36. PubMed ID: 36810108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of m6A Methylation Modification Patterns and Tumor Immune Microenvironment in Breast Cancer.
    Dong M; Shen W; Yang G; Yang Z; Li X
    Front Cell Dev Biol; 2022; 10():785058. PubMed ID: 35178386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in crosstalk between N6-methyladenosine (m6A) modification and circular RNAs in cancer.
    Huang X; Guo H; Wang L; Yang L; Shao Z; Zhang W
    Mol Ther Nucleic Acids; 2022 Mar; 27():947-955. PubMed ID: 35211355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. YT521-B homology domain family proteins as N6-methyladenosine readers in tumors.
    Yang H; Chiang C; Luo Q; Chen C; Huang J; Zhu L; Zheng D
    Front Genet; 2022; 13():934223. PubMed ID: 36017491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The implications of N6-methyladenosine (m6A) modification in esophageal carcinoma.
    He C; Teng X; Wang L; Ni M; Zhu L; Liu J; Lv W; Hu J
    Mol Biol Rep; 2023 Oct; 50(10):8691-8703. PubMed ID: 37598390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.